INTRODUCTION {#s1}
============

Thyroid cancer is the most common endocrine malignancy and its rate has been steadily increasing all over the world \[[@R1], [@R2]\]. The incidence of thyroid cancer more than doubled over the past 30 years in the United States (US) \[[@R3]\]. Davies et al. reported that the incidence of thyroid cancer was relatively stable until the early 1990s, after which its incidence increased remarkably due to an increase in PTCs \[[@R4]\]. The underlying causes of this increase are controversial. One proposal for the increasing incidence of thyroid cancer says it may be the result of two coexisting processes: increased diagnostic scrutiny and an increased number of cases due to unrecognized thyroid specific carcinogens \[[@R5]\]. Morris et al., however, stated that improved detection does not fully explain the rising incidence of thyroid cancer, and instead, a true increase in the incidence of thyroid cancer might be due to unknown hormonal, dietary, genetic or environmental risk factors \[[@R6]\].

In PTCs, the most common mutations are *BRAF* mutations, which were reported in 40-90% of cases from various geographical areas \[[@R7]--[@R9]\]. The second most common genetic alteration in PTC are *RET/PTC* rearrangements \[[@R10]\]. Both single- and multi-institutional studies in Italy, Korea and the US have shown a significant and steady increase in the prevalence of *BRAF* mutations \[[@R11]--[@R13]\]. On the other hand, *RAS* mutations have increased sharply, and *RET/PTC* rearrangements have steadily decreased over the years \[[@R11], [@R13], [@R14]\]. Marthur et al. also linked the increased *BRAF* mutation prevalence with increased thyroid cancer incidence \[[@R13]\]. However, it is still continuously debated whether the genetic background of PTC changed or not \[[@R14]\]. Therefore, we conducted this systematic literature review to investigate the worldwide trends of *BRAF* mutations, *RET/PTC* rearrangements and *RAS* mutations in PTCs.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

We identified 3139 results from the six libraries, but only 626 articles met our selection criteria. After carefully reading full-text versions of these 626 articles, we excluded 232 more studies. Overall, we listed and stratified 394 articles containing prevalence data of at least one genetic alteration into an excel file according to country, city, institution and the time period when surgery was performed. We used this listing to facilitate further data selection for analysis as described in each section below. To avoid overlapping patient data between publications with overlapping surgical time periods of patients from the same institution, we selected studies with the larger number of patients. Our final analysis included 16 studies (Figure [1](#F1){ref-type="fig"}).

![Flow diagram of study selection\
Abbreviations: WHO GHL, World Health Organization Global Health Library; VHL, Virtual Health Library.](oncotarget-08-10637-g001){#F1}

Trends for *BRAF* mutations, *RET/PTC* rearrangements and *RAS* mutations in classical PTCs from individual institutions {#s2_2}
------------------------------------------------------------------------------------------------------------------------

*BRAF* mutations have been reported to be associated with variants of PTCs: high prevalence in tall cell variant and classical PTCs and low prevalence in FVPTCs. In contrast, *RAS* mutations were reported as most commonly found in FVPTCs. Therefore, we examined the trends of *BRAF* mutations, *RET/PTC* rearrangements and *RAS* mutations in classical PTCs, the most common PTC variant, to avoid bias caused by other variants. We used the following criteria to select eligible data from the stratified list: (i) the study institution had available data on *BRAF* mutations, *RET/PTC* rearrangements or *RAS* mutations in classical PTCs from at least 2 different surgical time periods, (ii) the same detection method provided by the same manufacturer was used between the surgical time periods and (iii) patients with classical PTCs from all surgical periods received the same treatment (for example, all patients underwent total thyroidectomy) or the authors did not use any criteria that could influence the characteristics of classical PTCs during patient selection in each period.

We found appropriate *BRAF* data from two US institutions (University of California at San Francisco (UCSF) \[[@R13]\] and University of Pittsburgh \[[@R14]\]), an Italian multicenter study at the Endocrine Units of Pisa/Perugia/Milan \[[@R11]\], a Korean medical center (Seoul St. Mary\'s Hospital) \[[@R15], [@R16]\], an Irish institution (St. James\'s Hospital) \[[@R17]\] and an institution from Poland (Holycross Cancer Center) \[[@R18]\]. Prevalence of *BRAF* mutations in classical PTCs increased significantly in the studies from all of the institutions, except Seoul St. Mary\'s Hospital in Korea (Table [2](#T2){ref-type="table"}).

###### Characteristics of included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author / Year of publication / Country   Institution                                  Surgical Period   No. of cases   Mean of age   Tissue treatment method   Patient selection criteria                                                                                                                                                                                                                    Detection method\
                                                                                                                                                                                                                                                                                                                                                                                                               (Manufacturer)
  ---------------------------------------- -------------------------------------------- ----------------- -------------- ------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Mathur/2011/US \[[@R13]\]                University of California at San Francisco    1991 -- 1995\     74\            46.4\         Frozen\                   Consecutive patients underwent initial evaluation and treatment at the institution. Thyroidectomy was performed in all cases.                                                                                                                 BRAF, RAS: Direct sequencing (Applied Biosystem)\
                                                                                        1996 -- 2000\     103\           43.5\         Frozen\                                                                                                                                                                                                                                                                 RET/PTC: Nested PCR
                                                                                        2000 -- 2005      51             48.7          Frozen                                                                                                                                                                                                                                                                  

  Jung/2014/US \[[@R14]\]                  University of Pittsburgh                     1974 -- 1985\     62\            37.0 ^a^\     FFPE\                     Cases were chosen consecutively within each of preselected periods until the numeric target was fulfilled. No selection criteria of cPTCs were described.                                                                                     BRAF, RAS: Real-time LightCycler PCR and fluorescent melting curve analysis (Roche)\
                                                                                        1990 -- 1992\     22\            51.0 ^a^\     FFPE\                                                                                                                                                                                                                                                                   RET/PTC: Dual-color interphase FISH
                                                                                        2000\             24\            50.0 ^a^\     FFPE\                                                                                                                                                                                                                                                                   
                                                                                        2009              65             53.0 ^a^      FFPE                                                                                                                                                                                                                                                                    

  Romei/2012/Italy \[[@R11]\]              Endocrine units of Pisa, Perugia and Milan   1996 -- 2000\     56\            40.9\         Frozen\                   Cases were neither consecutive nor selected, and the same procedures of collection were followed in the three centers. No selection criteria of cPTCs were described.                                                                         BRAF: Direct sequencing (Applied Biosystem)\
                                                                                        2001 -- 2005\     98\            44.0\         Frozen\                                                                                                                                                                                                                                                                 RET/PTC: Southern blotting
                                                                                        2006 -- 2010      106            47.6          Frozen                                                                                                                                                                                                                                                                  

  Nam/2012/Korea \[[@R18]\]                Seoul St. Mary\'s Hospital                   2008 -- 2009      355            46.9          FFPE                      Thyroid tumor tissues were sampled from patients with PTC who underwent thyroidectomy. No selection criteria of cPTCs were described.                                                                                                         BRAF: Direct sequencing (Applied Biosystem)

  Lee/2014/Korea \[[@R19]\]                Seoul St. Mary\'s Hospital                   2011 -- 2012      200            45.7          FFPE                      The patients with PTC who underwent surgery at the institution during the selected time period were enrolled in this study. No selection criteria of cPTCs were described.                                                                    BRAF: Direct sequencing (Applied Biosystem)

  Smyth/2005/Ireland \[[@R20]\]            St. James\'s Hospital                        1982 -- 2003      18             49.6          FFPE                      Samples of PTC accessioned between 1982 -- 2003 were analysed. No selection criteria of cPTCs were described.                                                                                                                                 BRAF: Direct sequencing (Applied Biosystem)

  Kowalska/2016/Poland \[[@R21]\]          Holycross Cancer Center                      2000-2004\        152\           52.0 ^a^\     FFPE\                     Archived tumor tissue was retrieved from 785 unselected PTCs diagnosed between 2000-2013. No selection criteria of PTCs were described.                                                                                                       BRAF: Direct sequencing (Applied Biosystem), Allele-specific PCR and quantitative real time PCR (Qiagen)
                                                                                        2005-2009\        195\           53.0 ^a^\     FFPE\                                                                                                                                                                                                                                                                   
                                                                                        2010-2013         254            54.0 ^a^      FFPE                                                                                                                                                                                                                                                                    

  Nakazawa/2009/Japan \[[@R22]\]           University of Yamanashi                      2001 -- 2006      14             50.4          FFPE                      Surgical specimens were retrieved from the institution. A thorough review of clinical data revealed no history of radiation exposure. No selection critera of cPTCs were described.                                                           RET/PTC: Nested PCR

  Vuong/2016/Japan \[[@R23]\]              University of Yamanashi                      2011 -- 2014      59             49.3          FFPE                      We selected randomly patients with primary PTC who had been initially treated at the institution. No selection criteria of cPTCs were described.                                                                                              RET/PTC: Nested PCR

  Lee/2013/Korea \[[@R26]\]                Samsung Medical Center                       2008 -- 2009      396            47.0          FNAB                      Patients who underwent thyroidectomy for primary PTC during the time period were enrolled. No selection criteria of cPTCs were described.                                                                                                     BRAF: Direct sequencing (Applied Biosystem)

  Kang/2013/Korea \[[@R27]\]               Samsung Medical Center                       2010 -- 2011      128            48.0          FFPE                      Patients with PTC were randomly retrieved from the surgical pathology files. No selection criteria of cPTCs were described.                                                                                                                   BRAF: Direct sequencing (Applied Biosystem)

  Zheng/2013/China \[[@R24]\]              Tianjin Medical University Cancer Hospital   2001 -- 2010      977            46.0          FFPE                      A chart reviewed identified 2046 patients with PTC who underwent surgery during the time period. Among of them, 977 patients had PTMCs. No selection criteria of PTMCs were described.                                                        BRAF: Direct sequencing (Applied Biosystem)

  Lu/2013/China \[[@R25]\]                 Tianjin Medical University Cancer Hospital   2013 -- 2014      1984           45.0 ^a^      FFPE                      The clinical data was reviewed on 1990 PTMCs during the time period. No selection criteria of PTMCs were described.                                                                                                                           BRAF: Direct sequencing (Applied Biosystem)

  Barzon/2008/Italy \[[@R28]\]             University of Padova                         2005 -- 2007      83             43.6          Frozen                    Consecutive patients who underwent thyroidectomy at the institution in the selected period and had a pathological diagnosis of PTC. No selection criteria of PTCs were described.                                                             BRAF: Direct sequencing (Applied Biosystem)

  Pelizzo/2011/Italy \[[@R29]\]            University of Padova                         2008 -- 2009      270            48.9          FNAB                      Consecutive patients within selected time period were prospectively enrolled. All patients had a sonographic single node and/or a node with suspected features who underwent US-guided FNA and subsequent thyroidectomy at the institution.   BRAF: Direct sequencing (Applied Biosystem)

  Hwang/2009/Korea \[[@R30]\]              Samsung Medical Center                       2008              135            47.0          FNAB                      Consecutive patients with PTC that had been confirmed surgically were included in the study. All patients underwent ultrasound and ultrasound-guided FNA.                                                                                     BRAF: Direct sequencing (Applied Biosystem) and allele-specific PCR
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: cPTC, classical papillary thyroid carcinoma; PTMC, papillary thyroid microcarcinoma; FFPE, formalin-fixed paraffin embedded; FNAB, Fine-needle aspiration biopsy

^a^ Median value

###### The trends of BRAF mutations prevalence of classical PTCs from individual institutions

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country   City (State)           Institution\                                            Prevalence of *BRAF* mutations in classical PTCs                                                            
                                   (Reference)                                                                                                                                                         
  --------- ---------------------- ------------------------------------------------------- -------------------------------------------------- ------------------- ------------------- ---------------- ---------------
  US        San Francisco (CA)     UCSF \[[@R13]\]                                         1991-1995\                                         1996-2000\          2001-2005\                           **\<0.001**
                                                                                           38/74 (51.4%) DS                                   44/103 (42.7%)\     45/51 (88.2%)\                       
                                                                                                                                              DS                  DS                                   

  US        Pittsburgh (PA)        Univ. of Pittsburgh \[[@R14]\]                          1974-1985\                                         1990-1992\          2000\               2009\            **0.008** ^a^
                                                                                           31/62 (50.0%)\                                     16/22 (72.7%)\      17/24 (70.8%)\      50/65 (77.0%)\   
                                                                                           FMCA                                               FMCA                FMCA                FMCA             

  Italy     Pisa/ Perugia/ Milan   Endocrine units of Pisa, Milan and Perugia \[[@R11]\]   1996-2000\                                         2001-2005\          2006-2010\                           **0.012**
                                                                                           21/56 (37.5%)\                                     61/98 (62.2%)\      56/106 (52.9%)\                      
                                                                                           DS                                                 DS                  DS                                   

  Korea     Seoul                  Seoul St. Mary\'s Hospital \[[@R18], [@R19]\]           2008-2009\                                         2011-2012\                                               NS
                                                                                           283/355 (79.7%)\                                   165/200 (82.5%)\                                         
                                                                                           DS                                                 DS                                                       

  Ireland   Dublin                 St. James\'s Hospital \[[@R20]\]                        1982-1992\                                         1993-2002\                                               **0.043**
                                                                                           0/3 (0%)\                                          11/15 (73.3%)\                                           
                                                                                           DS                                                 DS                                                       

  Poland    Kielce                 Holycross Cancer Center \[[@R21]\]                      2000-2004\                                         2005 -- 2009\       2010 -- 2013\                        **0.001** ^a^
                                                                                           88/152 (57.9%)\                                    140/195 (71.8%)\    189/254 (74.4%)\                     
                                                                                           Three methods ^b^                                  Three methods ^b^   Three methods ^b^                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NS, not significant; DS, direct sequencing; FMCA, fluorescent melting curve analysis

^a^ P value for trend adjusted for age and sex

^b^ All analyses that were performed prior to 2013 by DS and allele-specific PCR (AS-PCR) were verified by quantitative Real time PCR (qPCR). In total, the authors used qPCR to analyze BRAF mutations in 705/723 PTCs (97.5%). The majority of samples were tested using the three methods (DS, AS-PCR and qPCR).

We gathered enough information to determine the trends of *RET/PTC* rearrangements in classical PTCs at UCSF \[[@R13]\] and University of Pittsburgh \[[@R14]\], the University of Yamanashi (Japan) \[[@R19], [@R20]\] and St. James\'s Hospital (Ireland) \[[@R17]\]. There was a decreasing trend of *RET/PTC* rearrangements over time in classical PTCs at all these institutions (Table [3](#T3){ref-type="table"}).

###### The trends of *RET/PTC* rearrangements prevalence of classical PTCs from individual institutions

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country   City (State)         Institution\                            Prevalence of *RET/PTC* rearrangements in classical PTCs                                                   
                                 (Reference)                                                                                                                                        
  --------- -------------------- --------------------------------------- ---------------------------------------------------------- ----------------- -------------- -------------- -------------
  US        San Francisco (CA)   UCSF \[[@R13]\]                         1991-1995\                                                 1996-2000\        2001-2005\                    **0.047**
                                                                         10/74 (13.5%)\                                             19/103 (18.4%)\   2/51 (3.9%)\                  
                                                                         Nested PCR                                                 Nested PCR        Nested PCR                    

  US        Pittsburgh (PA)      Univ. of Pittsburgh \[[@R14]\]          1974-1985\                                                 1990-1992\        2000\          2009\          NS
                                                                         6/52 (11.5%)\                                              1/18 (5.6%)\      2/23 (8.7%)\   1/65 (1.5%)\   
                                                                         DCI FISH                                                   DCI FISH          DCI FISH       DCI FISH       

  Japan     Yamanashi            Univ. of Yamanashi \[[@R22], [@R23]\]   2001-2006\                                                 2011-2014\                                      **\<0.001**
                                                                         4/14 (28.6%)\                                              1/59 (1.7%)\                                    
                                                                         Nested PCR                                                 Nested PCR                                      

  Ireland   Dublin               St. James\'s Hospital \[[@R20]\]        1982-1992\                                                 1993-2002\                                      NS
                                                                         2/3 (66.7%)\                                               4/15 (26.7%)\                                   
                                                                         RT-PCR                                                     RT-PCR                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DCI FISH, dual colour interphase fluorescent *in situ* hybridization; RT-PCR, reverse transcription PCR

We could determine the trends for *RAS* mutations in classical PTCs at UCSF \[[@R13]\] and University of Pittsburgh \[[@R14]\]. The prevalence of *RAS* mutations was low and gradually decreased from 4.1% during the 1991-1995 period to 0% during the 2001-2005 period (*p* = 0.369). At the University of Pittsburgh, the RAS mutation prevalence was extremely low and remained stable over four periods (Table [4](#T4){ref-type="table"}). *RAS* mutations are rarely detected in classical PTCs and therefore it can be difficult to observe the trend. As a result of this, we decided to further analyze the change of *RAS* mutations in FVPTCs from individual institutions. We could only gather information to determine the trend of *RAS* mutations in FVPTCs from University of Pittsburgh \[[@R14]\]. The prevalence of *RAS* mutations in FVPTCs was relatively stable during the first three periods but significantly increased from 11.1% in 2000 to 44.3% in 2009.

###### Trends of *RAS* mutations prevalence of classical PTCs from individual institutions

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country   City (State)         Institution\                     Prevalence of *RAS* rearrangements in classical PTCs                                                 
                                 (Reference)                                                                                                                           
  --------- -------------------- -------------------------------- ------------------------------------------------------ --------------- -------------- -------------- ----
  US        San Francisco (CA)   UCSF \[[@R13]\]                  1991-1995\                                             1996-2000\      2001-2005\                    NS
                                                                  3/74 (4.1 %)\                                          3/103 (2.9%)\   0/51 (0%)\                    
                                                                  DS                                                     DS              DS                            

  US        Pittsburgh (PA)      Univ. of Pittsburgh \[[@R14]\]   1974-1985\                                             1990-1992\      2000\          2009\          NS
                                                                  0/52 (0.0%)\                                           0/21 (0.0%)\    0.24 (0.0%)\   1/65 (1.5%)\   
                                                                  FMCA                                                   FMCA            FMCA           FMCA           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DS, direct sequencing; FMCA, fluorescent melting curve analysis

All individual institutions applied the same protocol for mutational tests (same tissue treatment method, same DNA extraction method and same mutational detection method from same manufacturer) between different periods.

Trends for *BRAF* mutations in micro PTCs from individual institutions {#s2_3}
----------------------------------------------------------------------

According to the WHO classification, micro PTCs are PTCs with a diameter ≤1cm. Data on the stratified list was eligible for selection in our review of micro PTCs if they met the same criteria as the criteria described above in classical PTCs section.

We could determine trends of the *BRAF* mutations in micro PTCs from four institutions. The *BRAF* mutation prevalence significantly increased at the Tianjin Medical University Cancer Hospital from 40.1% during 2001-2010 to 62.7% during 2013-2014, and investigators used direct sequencing for mutational analyses in both periods \[[@R21], [@R22]\]. Although the detection method for *BRAF* mutations was not disclosed within this study by Lu et al \[[@R22]\], the authors provided this information by email and confirmed that the PTC patients were recruited from Tianjin Medical University Cancer Hospital (an affiliated hospital of Tianjin Medical University). We also found the prevalence of *BRAF* mutations increased significantly at Samsung Medical Center \[[@R23], [@R24]\] and Holycross Cancer Center \[[@R18]\] (Table [5](#T5){ref-type="table"}). At the University of Pittsburgh, prevalence of *BRAF* mutations in micro PTCs decreased from 32.3% during 1974-1985 to 18.8% during 1990-1992 and then gradually increased to 23.5% in 2000 and 38% in 2009 \[[@R14]\]. This change, however, was not statistically significant (*p* = 0.442).

###### The trends of *BRAF* mutations prevalence of micro PTCs from individual institutions

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country   City (State)      Institution\                                               Prevalence of *BRAF* mutations in micro PTCs                                                        
                              (Reference)                                                                                                                                                    
  --------- ----------------- ---------------------------------------------------------- ---------------------------------------------- ------------------- ------------------ ------------- ---------------
  US        Pittsburgh (PA)   Univ. of Pittsburgh \[[@R14]\]                             1974-1985\                                     1990-1992\          2000\              2009\         NS
                                                                                         10/31(32.3%)\                                  3/16(18.8%)\        4/17 (23.5%)\      19/50(38%)\   
                                                                                         FMCA                                           FMCA                FMCA               FMCA          

  Poland    Kielce            Holycross Cancer Center \[[@R21]\]                         2000-2004\                                     2005-2009\          2010-2013\                       **0.001 ^b^**
                                                                                         45/90 (50%)\                                   104/147 (70.7)\     147/203 (72.4)\                  
                                                                                         Three methods ^a^                              Three methods ^a^   Three methods^a^                 

  Korea     Seoul             Samsung Medical Centre \[[@R26], [@R27]\]                  2008-2009\                                     2010-2011\                                           **0.013**
                                                                                         253/396(63.9%)\                                97/128(75.8%)\                                       
                                                                                         DS                                             DS                                                   

  China     Tianjin           Tianjin Medical Univ. Cancer Hospital \[[@R24], [@R25]\]   2001-2010\                                     2013-2014\                                           **\<0.001**
                                                                                         392/977(40.1%)\                                1244/1984(62.7%)\                                    
                                                                                         DS                                             DS                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NS, not significant; DS, direct sequencing; FMCA, fluorescent melting curve analysis

^a^ All analyses that were performed prior to 2013 by DS and allele-specific PCR (AS-PCR) were verified by quantitative Real time PCR (qPCR). In total, the authors used qPCR to analyze *BRAF* mutations in 705/723 PTCs (97.5%). The majority of samples were tested using the three methods (DS, AS-PCR and qPCR).

^b^ P value for trend adjusted for age and sex

All included institutions used the same protocol for mutational detection among different surgical periods but one exception (Samsung Medical Center) in which the DNA materials were extracted from fine-needle aspirates in the former period and from paraffin-embedded tissues in the latter. However, all PCR products in these two periods were visualized on 2% agarose gel to confirm the good DNA quality prior to DNA purification step \[[@R23], [@R24]\], thus minimized the influence of technical issues on the results of direct sequencing.

Trends of demographic and clinicopathological features and molecular profiles in PTCs over time {#s2_4}
-----------------------------------------------------------------------------------------------

To avoid bias, we only included articles with consecutive or random selection of patients and no criteria used in patient selection. We evaluated these trends only within individual institutions. We also excluded articles with consecutive or random selection of patients, but which focused on particular characteristics such as classical PTCs or patients who underwent total thyroidectomy or radioiodine ablation (possible bias toward aggressive PTCs and therefore could influence the nature of the PTC cohort). Five single- or multi-institutions met our criteria: University of Pittsburgh \[[@R14]\], University of Padua \[[@R25], [@R26]\], multicenter study from Pisa/Perugia/Milan \[[@R11]\], Samsung Medical Centre \[[@R24], [@R27]\] and Holycross Cancer Center \[[@R18]\].

Patients' ages at time of diagnosis increased during the most recent period at all included institutions. Another important finding is the significant increase in the proportion of micro carcinomas at all included institutions. The rates of ETE and lymph node metastasis (LNM) decreased at most of the institutions. The rate of multifocal PTCs stayed relatively stable over time (data not shown). Table [6](#T6){ref-type="table"} describes changes in demographic data and clinicopathological features of PTCs over time.

###### Modifications of demographic and clinicopathological characteristics of PTCs over time from individual institutions

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country   Institution\                                        Period       Patients' age (years)   *p*           Male\   *p*   Tumor size\    *p*           FVPTC (%)   *p*           ETE\         *p*         LNM\    *p*
            (Reference)                                                                                            (%)           (%)                                                    (%)                      (%)     
  --------- --------------------------------------------------- ------------ ----------------------- ------------- ------- ----- -------------- ------------- ----------- ------------- ------------ ----------- ------- -------------
  US        University of Pittsburgh\[[@R14]\]                  1974-1985\   Median, 37\             **\<0.001**   27.6\   NS    ≤1cm, 42.0\    NS            10.2\       **\<0.001**   40.2\        **0.005**   26.8\   **\<0.001**
                                                                1990-1992\   Median, 37\                           27.1\         ≤1cm, 44.1\                  3.4\                      27.1\                    28.8\   
                                                                2000\        Median, 50\                           13.2\         ≤1cm, 41.5\                  13.2\                     26.9\                    20.8\   
                                                                2009         Median, 53                            24.5          ≤1cm, 51.3                   25.2                      20.9                     18.3    

  Italy     University of Padua\[[@R28], [@R29]\]               2005-2007\   Mean, 43.6\*\           **0.003**     28.9\   NS    ND\            NA            3.6\        NS            ND\          NA          51.8\   **0.049**
                                                                2008-2009    Mean, 49.0                            22.7          ≤1cm, 24.9                   3.5                       45.4                     38.3    

  Italy     Endocrine units of Pisa/Perugia/ Milan \[[@R11]\]   1996-2000\   Mean, 40.9\             **0.014**     32.0\   NS    \<2cm, 43.3\   **0.01**      12.3\       NS            T3/T4, 45\   **0.005**   50.7\   NS
                                                                2001-2005\   Mean, 44.0\                           25.0\         \<2cm, 59.4\                 18.4\                     T3/T4, 39\               48.1\   
                                                                2006-2010    Mean, 47.6                            32.7          \<2cm, 61.0                  15.3                      T3/T4, 35                51.9    

  Poland    Holycross Cancer Center \[[@R21]\]                  2000-2004\   Median, 50\             NS            11.3\   NS    ≤1cm, 50.8\    **0.003**     11.3\       NS            22.5\        NS          12.4\   NS
                                                                2005-2009\   Median, 53\                           11.6\         ≤1cm, 63.1\                  12.9\                     25.3\                    12.9\   
                                                                2010-2013    Median, 53                            13.1          ≤1cm, 64.9                   15.0                      24.9                     13.7    

  Korea     Samsung Medical Centre\[[@R27], [@R30]\]            2008\        Mean, 47.0\             NS            18.5\   NS    ≤1cm, 55.6\    **\<0.001**   2.9\        NA            62.2\        NS          48.1\   **0.043**
                                                                2010-2011    Mean, 48.0                            16.9          ≤1cm, 80.5                   ND                        53.5                     36.5    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: FVPTC, follicular variant papillary thyroid carcinoma; ETE, extrathyroidal extension; LNM, Lymph node metastasis; NS, not significant; NA, not available; ND, not described

\* Estimated the sample mean and standard deviation as described by Hozo *et al*. \[[@R16]\]

Quality assessment and risk of bias analysis {#s2_5}
--------------------------------------------

The quality score ranged from 40% to 70%, as measured by the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies \[[@R28]\]. The lowest scored was 40% (Nakazawa et al. \[[@R19]\]) and the highest score was 70% (Jung et al. \[[@R14]\]). Quality of all included articles were classified as fair, except the two studies by Smyth et al. \[[@R17]\] and Nakazawa et al. \[[@R19]\] which were regarded as low quality. Most of included studies lacked sample size justification. Quality scores for each NIH criteria are shown in [Supplementary Table](#SD1){ref-type="supplementary-material"}.

DISCUSSION {#s3}
==========

The incidence of thyroid cancer has been increasing at an amazing rate in recent decades, especially PTCs \[[@R3], [@R4]\]. There is still debate as to whether improved detection is the only reason for the increase of PTCs or whether the tumorigenesis of thyroid cancer has changed \[[@R3], [@R6]\]. From our findings, the basic nature of PTC has been changing in recent decades (Table [6](#T6){ref-type="table"}). The increase in the proportion of microcarcinomas that are diagnosed is associated with the improved detection rate in recent years, especially the development of ultrasonography. The majority of microcarcinomas show indolent behaviors, which can explain our findings that PTCs manifested less aggressive behaviors in the most recent periods we analyzed.

With improved screening and detection methods, it is reasonable to believe that patients would be diagnosed at an earlier age. However, our analysis suggests the opposite result. A number of publications showed that *BRAF* mutations are found in a higher proportion of older patients \[[@R12], [@R29]--[@R34]\], and *RET/PTC* rearrangements are commonly found in young patients \[[@R35]--[@R37]\]. Our systematic review demonstrated an increased prevalence of *BRAF* mutations (typically older patients) accompanied by a decreased prevalence of *RET/PTC* rearrangements (typically young patients).

Other than the multicenter study from the endocrine units of Pisa/Perugia/Milan \[[@R11]\] and the study from Holycross Cancer Center \[[@R18]\], the male proportion of patients with thyroid cancer has been decreasing over the years, although the difference was not significant (Table [6](#T6){ref-type="table"}). Recent data showed that the increased incidence in thyroid cancer has affected more women than men, which supports our findings \[[@R3], [@R4]\].

There is still the question as to why the prevalence of *BRAF* mutations has been increasing significantly and the prevalence of *RET/PTC* rearrangements has been falling over the years. It is difficult to address the possible reasons for these changes because there are no known etiologies or risk factors that could trigger or activate these genetic alterations in PTCs other than radiation-induced *RET/PTC* \[[@R38]\]. From our findings, the significant increase of *BRAF* mutations in classical PTCs has occurred in different geographical areas (Table [2](#T2){ref-type="table"}). Interestingly, we also found a remarkable increase of *BRAF* mutations in micro PTCs from Kielce, Seoul and Tianjin (Table [5](#T5){ref-type="table"}). Elisei et al. suggested worldwide iodine supplementation as a potential candidate for the worldwide increasing trend of *BRAF* mutations \[[@R39]\]. How iodine intake may influence *BRAF* mutations in PTCs, however, is still controversial. Guan et al. reported that high iodine intake was associated with a higher prevalence of the *BRAF V600E* mutation in Chinese PTCs \[[@R40]\]. To the best of our knowledge, this is the only publication that linked iodine intake with occurrence of *BRAF* mutations. Frasca et al. reported there was no statistical difference in *BRAF V600E* prevalence in Italian PTCs from iodine-sufficient *vs*. iodine-deficient areas \[[@R8]\]. Data collected from the US showed that the US population has sufficient iodine intake \[[@R41], [@R42]\]. Because of this, it is irrational to correlate the increasing trend of *BRAF* mutations in classical PTCs seen in California and Pittsburgh with iodine intake. In our recent study, we found no statistical significance in the prevalence of *BRAF V600E, RET/PTC* rearrangements or *RAS* mutations in papillary and follicular thyroid carcinomas from an iodine-rich country (Japan) and an iodine-deficient country (Vietnam) \[[@R20]\]. Research in recent decades has increased our understanding of the molecular pathogenesis of thyroid cancer \[[@R1], [@R10], [@R43]\]. However, the origin of *BRAF* mutations in thyroid cancer still needs clarification. Further experimental studies should better clarify the origin of these mutations and help determine the reasons behind the increase in *BRAF* mutations over the last few decades.

A significant decrease of *RET/PTC* rearrangements in classical PTCs has been seen over the years (Tables [3](#T3){ref-type="table"}). *RET/PTC* rearrangements have been strongly associated with radiation-induced PTCs \[[@R35], [@R44], [@R45]\]. *RET/PTC* rearrangements could also be detected in sporadic PTCs, but the underlying causes are unknown. A worldwide decrease in exposure to ionizing radiation in recent years, long after the Chernobyl accident or nuclear test experiments, has been proposed as a possible reason for the decrease of *RET/PTC* rearrangements \[[@R39]\]. Another hypothesis is that *RET/PTC* rearrangements are induced by unknown determinants that have been changing over the last decades \[[@R39]\]. We are in favor of the latter hypothesis because there were no nuclear accidents or atomic bomb experiments in the UK, Italy or Japan that could explain the high prevalence of *RET/PTC* rearrangements in sporadic PTCs in the earlier period of our review. In recent years, there has been another nuclear accident in Fukushima (Japan) in March 2011. *BRAF* mutations were the major genetic event (63.2%) in pediatric PTCs in Fukushima who underwent thyroidectomy in 2013 - 2014 and *RET/PTC* rearrangements were found in only 10.3% of cases \[[@R46]\]. This oncogenic profile is quite different from Chernobyl-related studies \[[@R47]\] but this result should be interpreted with cautions. Firstly, the thyroid equivalent doses in Fukushima (4.2 mSV) is much lower than in Chernobyl (490 mSV) \[[@R48], [@R49]\]. The second issue is that at the time of the study by Mitsutake et al. \[[@R46]\], the interval period from the date of accident to the onset was too short. Continuous studies are required to further investigate the trends of thyroid cancer incidence and genetic alterations in Japanese children.

At the University of Pittsburgh, the frequency of *RAS* mutations in PTCs remained low and stable during 1974-2000, then significantly increased in 2009 \[[@R14]\]. This trend was accompanied by a remarkable increase of FVPTCs in 2009 (Table [6](#T6){ref-type="table"}). The incidence of FVPTC was reported to have increased nearly three-fold from 1973 to 2003 in the US \[[@R50]\]. Most of the increase in FVPTCs occurred after 1988 when the WHO classification changed. However, the proportion of FVPTCs did not change in Italy over the years \[[@R11]\]. We can only examine the trend of *RAS* mutations in classical PTCs from UCSF and University of Pittsburgh. The prevalence of *RAS* mutations did not change in classical PTCs from the University of Pittsburgh over the four periods in our review, but its prevalence in FVPTCs did increase significantly from 11.1% in 2000 to 44.3% in 2009 \[[@R14]\]. The authors from UCSF only selected patients with classical PTCs for their study, and they identified *RAS* mutations in 4%, 2.9% and 0% of cases during 1991 to 1995, 1996 to 2000 and 2001 to 2005, respectively (Table [4](#T4){ref-type="table"}). Further studies should examine the trend of *RAS* mutations in PTCs, especially the follicular variant or follicular neoplasms (follicular thyroid adenoma and carcinoma).

Our systematic review is limited by the relatively small number of institutions that can be included. However, we must apply strict criteria as described above to avoid the potential bias caused by heterogeneities in population characteristics, detection methods and other factors that could influence the prevalence of genetic alterations. Further population-based studies with large number of cases are required to clarify these trends. In addition, we could not perform multivariate analysis for trends of mutations adjusted for the confounding factors because most of included studies did not provide those data or individual patient data. Jung et al. and Kowalska et al. investigated the trend of mutations in classical PTCs adjusted for age and sex and they found a significant increase of *BRAF* mutations over time \[[@R14], [@R18]\] (Table [2](#T2){ref-type="table"}).

From our study, it is evident that the demographic and clinicopathological characteristics and the molecular profiles of PTCs have been changing over the years worldwide, suggesting the changes in tumorigenesis of PTCs. Further research on whether the genetic alterations in PTCs are primary or secondary and elucidation of molecular pathways in the pathogenesis of thyroid cancer can help us clarify the underlying causes of these modifications.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and study identification {#s4_1}
----------------------------------------

We conducted an electronic search within six databases (PubMed, Scopus, ISI Web of Science, Google Scholar, WHO Global Health Library and Virtual Health Library) to identify relevant articles using the search term: (papillary thyroid AND (carcinoma OR cancer) AND (BRAF OR RAS OR RET/PTC). We did not limit the search results as to language or year of publication. Our study included publications published before June 2015. Additionally, we performed a manual search by reviewing citations within the included publications and related references presented in PubMed. Our study strictly followed the recommendation of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement \[[@R51]\]. We registered our study protocol at PROSPERO database: <http://www.crd.york.ac.uk/prospero/display_record.asp?ID=RD42015024778>.

Selection criteria {#s4_2}
------------------

We imported search results from 6 libraries into Endnote (Thompson Reuters) and deleted duplicates. Two teams of reviewers independently screened the abstracts using the predetermined selection criteria. The inclusion criteria were (i) articles containing data regarding frequencies of *BRAF* mutations, *RET/PTC* rearrangements or *RAS* mutations in PTCs or classical PTCs which had been histologically confirmed, (ii) articles containing data regarding frequencies of *RAS* mutations in follicular variant PTCs (FVPTCs) or (iii) articles comparing the clinicopathological characteristics of PTCs between different time periods. We excluded studies that (i) did not provide the locations or institutions where the patients with PTC were recruited or treated, (ii) focused only on a histological variant (with two exceptions described in the inclusion criteria) or a clinicopathological factor (e.g. pediatric PTCs, multifocal PTCs or recurrent PTCs), (iii) involved radiation-induced PTCs unless the study had a mixed population of radiation-induced and sporadic PTCs with the sporadic PTC data reported separately, (iv) were experimental or *in vitro* in nature, (v) were case reports, conference presentations, posters, proceeding papers, books, theses or reviews or (vi) duplicated data. If a study\'s authors did not indicate where patients' data was collected or where they were treated and all authors were from the same affiliation, the affiliation location was considered the primary place where the patients were initially treated.

Data extraction {#s4_3}
---------------

Two teams of reviewers independently read the full text of potential articles and extracted data using a predefined data extraction form. Supervisors resolved any discrepancies during this data extraction step. We extracted the following details: name of institution, city, country, time of surgery (when the patient was admitted), patient\'s age and gender, patient selection method, mutational detection method, prevalence of genetic alterations in entire PTC population and each histological variant, and clinicopathological data (histological variants, size, multiplicity, extrathyroidal extension (ETE) and TNM classification). We sought missing data from potentially eligible studies *via* email with the authors. If the full text did not indicate when patients received surgery and the authors did not respond to our emails, we considered time before submission date of the article as a patient\'s surgical time period. Native speakers from a group of international doctors extracted data from articles not written in English, and this was further checked by Google Translate.

Data analysis {#s4_4}
-------------

Our systematic literature review assessed several factors: 1) *BRAF, RET/PTC* and *RAS* mutational trends in classical PTCs from individual institutions; 2) *BRAF* mutational trends in micro PTCs from individual institutions; 3) modifications and trends of clinicopathological characteristics of PTCs from individual institutions. Selection and analysis of data for each section is described in detail below.

We compared the means and standard deviations (SD) of age and tumor size by using Student *t* test in GraphPad QuickCals at <http://www.graphpad.com/quickcalcs/ttest1.cfm?Format=SD> For those articles in which the authors only provided median, range and the total number of patients, we estimated mean and SD values as described by Hozo et al \[[@R52]\]. Pearson Chi-square was used to compare the clinicopathological features and prevalence of each mutation between different periods from the same institutions. Statistical analysis was performed with the SPSS software, version 22 (Chicago, IL). A *p* value ≤ 0.05 was considered statistically significant.

Quality assessment and risk of bias analysis {#s4_5}
--------------------------------------------

Two investigators independently scored the quality and risk of bias of the included studies, as measured by the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies of the National Institute of Health (NIH) \[[@R28]\]. Disagreements in scoring was solved by discussion and consensus. The score of all 14 items marked with "yes" were calculated into percentage (inapplicable items were not taken into account). The quality rating of included studies was classified as low, fair and good if the score percentage was lower than 50%, 50% - 75% and more than 75%, respectively.

SUPPLEMENTARY TABLE {#s5}
===================
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